Lauren K Wood Heickman1, Ladan Davallow Ghajar1, Mark Conaway2, Alan D Rogol1. 1. Department of Pediatrics, Division of Endocrinology, University of Virginia, Charlottesville, Virginia, USA. 2. Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA.
Abstract
BACKGROUND/AIMS: A meta-analysis was performed to determine the likelihood of hypothalamic-pituitary-adrenal (HPA) axis suppression following short-term cutaneous treatment of atopic dermatitis with topical corticosteroids (TCS) in pediatric patients. METHODS: All published pediatric clinical trials evaluating TCS use with pre- and post-treatment HPA axis assessment by cosyntropin stimulation testing were included. RESULTS: Of 128 eligible trials, 12 were selected for meta-analysis with a total of 522 participants. There were 20 observed cases of HPA axis suppression (3.8%, 95% CI 2.4-5.8). The percentage of HPA axis suppression with low- (classes 6-7), medium- (classes 3-5) and high-potency (classes 1-2) TCS use was 2% (3 of 148 patients, 95% CI 0.7-5.8), 3.1% (7 of 223 patients, 95% CI 1.5-6.3), and 6.6% (10 of 151 patients, 95% CI 3.6-11.8), respectively. CONCLUSION: There is a low rate of reversible HPA axis suppression with the use of mid- to low-potency TCS compared to more potent formulations. In pediatric clinical practice, the limited use of mid- to low-potency TCS is rarely associated with clinically significant adrenal insufficiency or adrenal crisis. In the absence of signs and symptoms of adrenal insufficiency, there is little need to test the HPA axis of these patients.
BACKGROUND/AIMS: A meta-analysis was performed to determine the likelihood of hypothalamic-pituitary-adrenal (HPA) axis suppression following short-term cutaneous treatment of atopic dermatitis with topical corticosteroids (TCS) in pediatric patients. METHODS: All published pediatric clinical trials evaluating TCS use with pre- and post-treatment HPA axis assessment by cosyntropin stimulation testing were included. RESULTS: Of 128 eligible trials, 12 were selected for meta-analysis with a total of 522 participants. There were 20 observed cases of HPA axis suppression (3.8%, 95% CI 2.4-5.8). The percentage of HPA axis suppression with low- (classes 6-7), medium- (classes 3-5) and high-potency (classes 1-2) TCS use was 2% (3 of 148 patients, 95% CI 0.7-5.8), 3.1% (7 of 223 patients, 95% CI 1.5-6.3), and 6.6% (10 of 151 patients, 95% CI 3.6-11.8), respectively. CONCLUSION: There is a low rate of reversible HPA axis suppression with the use of mid- to low-potency TCS compared to more potent formulations. In pediatric clinical practice, the limited use of mid- to low-potency TCS is rarely associated with clinically significant adrenal insufficiency or adrenal crisis. In the absence of signs and symptoms of adrenal insufficiency, there is little need to test the HPA axis of these patients.
Authors: Cathrine Helene Mohn; Hege S Blix; Anja Maria Brænd; Per Nafstad; Ståle Nygard; Jon Anders Halvorsen Journal: Dermatol Ther (Heidelb) Date: 2022-06-28
Authors: Stephanie J Lax; Jane Harvey; Emma Axon; Laura Howells; Miriam Santer; Matthew J Ridd; Sandra Lawton; Sinéad Langan; Amanda Roberts; Amina Ahmed; Ingrid Muller; Long Chiau Ming; Saumya Panda; Pavel Chernyshov; Ben Carter; Hywel C Williams; Kim S Thomas; Joanne R Chalmers Journal: Cochrane Database Syst Rev Date: 2022-03-11
Authors: Stefan Eirefelt; Martin Stahlhut; Naila Svitacheva; Martin A Carnerup; Joel Mauricio Correa Da Rosa; David Adrian Ewald; Troels T Marstrand; Mikkel Krogh-Madsen; Georg Dünstl; Kevin Neil Dack; Anna Ollerstam; Hanne Norsgaard Journal: Sci Rep Date: 2022-01-27 Impact factor: 4.379
Authors: Alexandra Ahmet; Arati Mokashi; Ellen B Goldbloom; Celine Huot; Roman Jurencak; Preetha Krishnamoorthy; Anne Rowan-Legg; Harold Kim; Larry Pancer; Tom Kovesi Journal: BMJ Paediatr Open Date: 2019-10-23
Authors: Emma Axon; Joanne R Chalmers; Miriam Santer; Matthew J Ridd; Sandra Lawton; Sinead M Langan; Douglas J C Grindlay; Ingrid Muller; Amanda Roberts; Amina Ahmed; Hywel C Williams; Kim S Thomas Journal: BMJ Open Date: 2021-07-07 Impact factor: 2.692